Orlov S Nicole Schaeffer sold $15M of INSM
Chief People Strategy Officer at INSMED Inc. 87,290 shares at an average of $175.20, traded Jan 2, 2026, filed Jan 6, 2026.
Score components
- +15RoleOfficer
- +25Trade size$15.3M at market
- +20Share of holdings soldSold 68% of holdings
- +15Cluster6 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -13.7%, 3m -6.9%, 6m -35.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001401017-26-000002, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 2, 2026 | AGrant or award Common Stock10b5-1 | +5,293 | - | - | 41,754 | Jan 6, 2026 |
| Jan 2, 2026 | MOption exercise Common Stock10b5-1 | +87,290 | $13.91 | $1.2M | 129,044 | Jan 6, 2026 |
| Jan 2, 2026 | SOpen-market sale Common Stock10b5-1 | -31,030 | $174.28 | $5.4M | 98,014 | Jan 6, 2026 |
| Jan 2, 2026 | SOpen-market sale Common Stock10b5-1 | -34,103 | $175.17 | $6.0M | 63,911 | Jan 6, 2026 |
| Jan 2, 2026 | SOpen-market sale Common Stock10b5-1 | -12,832 | $176.08 | $2.3M | 51,079 | Jan 6, 2026 |
| Jan 2, 2026 | SOpen-market sale Common Stock10b5-1 | -9,125 | $177.17 | $1.6M | 41,954 | Jan 6, 2026 |
| Jan 2, 2026 | SOpen-market sale Common Stock10b5-1 | -200 | $177.78 | $36k | 41,754 | Jan 6, 2026 |
| Jan 2, 2026 | AGrant or award Stock Option (right to buy)derivative10b5-1 | +27,600 | $0.00 | $0 | 27,600 | Jan 6, 2026 |
| Jan 2, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -87,290 | $0.00 | $0 | 0 | Jan 6, 2026 |
Related signals
Other insiders at INSMED Inc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | INSMsell INSMED Inc | David R Brennan director | $3.1M 25,000 shares | -39% | |
| 70Notable | INSMED Inc | Melvin Sharoky Md director | $638k 5,000 shares | -100% | |
| 65Notable | INSMED Inc | Roger Adsett Chief Operating Officer | $32M 239,850 shares | -71% | |
| 30Weak | INSMED Inc | Martina Flammer M.D. Chief Medical Officer | $3.5M 27,173 shares | -31% | |
| 23Weak | INSMED Inc | William Lewis Chair and CEO | $1.1M 10,700 shares | -4% | |
| 23Weak | INSMED Inc | William Lewis Chair and CEO | $1.3M 10,699 shares | -4% | |
| 25Weak | INSMED Inc | Martina Flammer M.D. Chief Medical Officer | $1.4M 12,302 shares | -17% | |
| 30Weak | INSMED Inc | William Lewis Chair and CEO | $2.2M 21,398 shares | -8% | |
| 21Weak | INSMED Inc | Michael Alexander Smith Chief Legal Officer | $173k 1,806 shares | -5% | |
| 40Moderate | INSMED Inc | William Lewis Chair and CEO | $613k 6,515 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.